Table 1.
The Main Preclinical Studies Investigating the Potential Breakthroughs of NIR-PIT for Breast Cancers.
| Antigen targeted | Conjugated | Cell lines used in in vivo experiments | Year |
|---|---|---|---|
| EGFR17 | Anti-EGFR (Cetuximab) moAb | MDAMB231, MDAMB468 | 2015 |
| EGFR34 | Anti-EGFR (Panitumumab) moAb | MDA-MB468 | 2018 |
| EGFR35 | Anti-EGFR (Cetuximab) moAb | BT-20, MDA-MB453 | 2021 |
| CD4436 | Anti-CD44 moAb | MDA-MB-231, BT-474 | 2016 |
| HER237 | Anti-HER2 (Trastuzumab) moAb | SKBR3, MDA-MB-231, and MCF7 | 2014 |
| HER238 | Anti-HER2 (Trastuzumab) moAb | BALB/3T3 cells, HCC-1419 cells | 2017 |
| HER239 | HER2 Affibody | SK-BR3, BT474, MDA-MB361 | 2019 |
| HER240 | Anti-HER2 (Trastuzumab) moAb and HER2 Affibody | SK-BR3, MDA-MB361, JIMT1 | 2021 |
| CD20641 | Anti-CD206 moAb | 4T1 | 2016 |
| ICAM-142 | Anti- ICAM-1 moAb | MDAMB468-luc, MDAMB231 cells | 2022 |
| FAP-α43 | Anti-CD44 moAb (AF3715) | MDA-MB-231 | 2022 |
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor-2; ICAM-1, intercellular adhesion molecule-1; FAP-α, fibroblast activation protein alpha.